Results 151 to 160 of about 387,784 (165)

[Building a semFYC for the future]. [PDF]

Aten Primaria, 2019
Junta Permanente de semFYC. Electronic address: stranchei@semfyc.es.
europepmc   +1 more source

Not a Sip: Effects of Zero Tolerance Laws on Road Traffic Fatalities. [PDF]

Health Econ
Ramasco A.
europepmc   +1 more source

[Reputational risks associated with nurses' presence on social media: proposed actions following the Vall d'Hebron case]. [PDF]

An Sist Sanit Navar
González-Luis H, Azurmendi A, Basanta-Vázquez B, Pujol F.   +3 more
europepmc   +1 more source

A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates. [PDF]

Front Immunol, 2014
Ambuel Y, Young G, Brewoo JN, Paykel J, Weisgrau KL, Rakasz EG, Haller AA, Royals M, Huang CY, Capuano S, Stinchcomb DT, Partidos CD, Osorio JE.   +12 more
europepmc   +1 more source

Adherence to colorectal cancer screening in a private health insurance center in Argentina from 2008 to 2022. [PDF]

Rev Peru Med Exp Salud Publica
Sguiglia S, Volij C, Rodríguez-Tablado M, Terrasa S, Esteban S.   +4 more
europepmc   +1 more source

CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate. [PDF]

J Infect Dis, 2015
Chu H, George SL, Stinchcomb DT, Osorio JE, Partidos CD.   +4 more
europepmc   +1 more source

Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates. [PDF]

PLoS Negl Trop Dis, 2016
Strouts FR, Popper SJ, Partidos CD, Stinchcomb DT, Osorio JE, Relman DA.   +5 more
europepmc   +1 more source

Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice. [PDF]

Vaccine, 2014
Fuchs J, Chu H, O'Day P, Pyles R, Bourne N, Das SC, Milligan GN, Barrett AD, Partidos CD, Osorio JE.   +9 more
europepmc   +1 more source